New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis

    NEXT STORY
    Immunicum AB (publ) Delårsrapport för första kvartalet (januari-mars 2020)
    PREV STORY
    First patient dosed in avdoralimab Phase II clinical trial in COVID-19 patients with severe pneumonia
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility

    SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a ...

    author_avatar
    NASDAQ Market News

    Aspen Valley Hospital and The Steadman Clinic Form Strategic Partnership

    author_avatar
    NASDAQ Market News

    Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019

    author_avatar
    NASDAQ Market News